News
Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...
6don MSN
The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, ...
Switzerland’s medical products authority has granted the first approval for a malaria medicine designed for small infants ...
Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.
The company's quarterly core operating profit--the company's preferred earnings metric, which strips out exceptional and other one-off items--is forecast at $5.75 billion, according to the same ...
7h
Zacks Investment Research on MSNWill Key Drugs Maintain Momentum for Novartis in Q2 Earnings?Novartis AG NVS, a Swiss pharma giant, is scheduled to report second-quarter 2025 results on July 17. The Zacks Consensus ...
Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...
Monday was Kate Walsh’s first day in semi-retirement. As Massachusetts secretary of health and human services, she oversaw a ...
1d
NDTV Profit on MSNDivi's Labs Shares Slide After Novartis' Entresto Loses Patent LawsuitDivi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based ...
A Delaware federal judge has ruled that Novartis cannot prevent MSN Pharmaceuticals from introducing a generic version of its ...
Novartis made one of the biggest investments in Cannes among pharma companies, sending approximately 20 people from the organization to the creativity festival. They came with multiple goals, ...
Novartis has inked a deal with Sironax that gives the pharma the exclusive option to acquire the biotech’s blood-brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results